nccRCC

Ongoing Clinical Trials in Rare GU Malignancies
Andrea B. Apolo, MD, of National Cancer Institute, shares the trials in progress she presented at the 2024 American Society of Clinical Oncology Annual Meeting, including SMART, LASER, and E-VIRTUE. SMART is a phase 2 study of sacituzumab govitecan with or without atezolizumab immunotherapy in rare genitourinary tumors, including small cell adenocarcinoma, squamous cell bladder/urinary tract cancer, renal medullary carcinoma, and penile cancer. ...
Advertisement
Advertisement

RCC Knowledge Hubs

Renal Cell Carcinoma
Renal Cell Carcinoma

Conference Coverage

Advertisement
Advertisement
Latest News